Takeda Pharmaceutical (TAK) Net Income Growth (1y) (2018 - 2026)
Takeda Pharmaceutical (TAK) Net Income Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -105.67% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -99.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.83% |
| Mar 31, 2026 | 7.57% |
| Dec 31, 2025 | -252.45% |
| Sep 30, 2025 | 17.15% |
| Jun 30, 2025 | 7.02% |
| Mar 31, 2025 | 2.31% |
| Dec 31, 2024 | -4,440.99% |
| Sep 30, 2024 | 22.10% |
| Jun 30, 2024 | -13.31% |
| Mar 31, 2024 | -21.06% |
| Dec 31, 2023 | -96.58% |
| Sep 30, 2023 | 297.92% |
| Jun 30, 2023 | -17.21% |
| Mar 31, 2023 | -41.30% |
| Dec 31, 2022 | -11.55% |
| Sep 30, 2022 | -30.17% |
| Jun 30, 2022 | -43.45% |
| Mar 31, 2022 | 232.37% |
| Dec 31, 2021 | -37.42% |
| Sep 30, 2021 | 648.22% |